Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

NCT04402073 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

NETWORK

Sponsor class

Stopped Poor accrual

Conditions

Medulloblastoma

Interventions

DRUG: Sonidegib
DRUG: Cisplatin
DRUG: Lomustine
DRUG: Vincristine
RADIATION: radiotherapy

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC